Receptor tyrosine-protein kinase ERBB2 (HER2) is a well-known immunotherapy target that is overexpressed in multiple adult and pediatric cancers [4–7], including approximately 40% of medulloblastoma. The gene discussed is ERBB2; the disease is medulloblastoma.